CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016--
AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey,
president and chief executive officer, will present at Biotech Showcase
2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55
Wyndham in San Francisco.
A live webcast of AVEO’s presentation can be accessed by visiting the
investors section of the company’s website at www.aveooncology.com.
A replay of the webcast will be archived for 30 days following the
AVEO Oncology (AVEO) is a biopharmaceutical company committed to
developing targeted therapies through biomarker-driven insights to
provide improvements in patient outcomes where significant unmet medical
needs exist. AVEO’s proprietary Human Response Platform™ has delivered
unique insights into cancer and related disease biology that AVEO is
seeking to leverage in the clinical development strategy of its
therapeutic candidates. For more information, please visit the company’s
website at www.aveooncology.com.
AVEO Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within
the meaning of The Private Securities Litigation Reform Act of 1995 that
involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Actual results or events could differ
materially due to a number of important factors, including risks
discussed in the section titled “Risk Factors” in AVEO’s most recent
Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its
other filings with the SEC. The forward-looking statements in this press
release represent AVEO’s views as of the date of this press release.
AVEO anticipates that subsequent events and developments may cause its
views to change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any date
other than the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106005447/en/
Source: AVEO Oncology
David Pitts, (212) 600-1902